Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Core Findings - Telomir Pharmaceuticals has expanded the oncology profile of its investigational compound Telomir-1 to include aggressive human leukemia cells, in addition to its previously reported efficacy in triple-negative breast cancer, pancreatic cancer, and aggressive prostate cancer models [1] Company Overview - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapies that target the epigenetic and metabolic roots of cancer, aging, and age-related diseases [1]